Welling­ton Part­ners tanks up with $237M for its next life sci fund — same strat­e­gy, but with more cash on hand

A year ago, when Philadel­phia-based Caris­ma Ther­a­peu­tics was rais­ing a $53 mil­lion A round to back their work on macrophages in im­muno-on­col­o­gy, Mu­nich-based Welling­ton Part­ners …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER